Skip to main content
SpringerLink
Log in

The Science and Regulations of Naturally Derived Complex Drugs

  • Book
  • © 2019

Overview

Editors:
  1. Ram Sasisekharan

    1. Department of Biological Engineering, Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Sau L. Lee

    1. Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Amy Rosenberg

    1. Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  4. Larry A. Walker

    1. Director Emeritus, National Center for Natural Products Research, School of Pharmacy, University of Mississippi, Oxford, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Addresses the regulatory science specific to complex drug products including quality, safety and clinical aspects
  • Discusses raw materials, manufacturing. quality control, impurities, toxicity, immunogenicity, clinical trials and regulatory aspects
  • Presents a roadmap for the future development of complex mixtures for medicinal use

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series (AAPS, volume 32)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (18 chapters)

  1. Front Matter

    Pages i-vi
    Download chapter PDF

  2. Evolving Challenges in Developing Naturally-Derived Complex Mixtures into Drugs: U.S. Experience and Perspective

    • Adam C. Fisher, Sau L. Lee
    Pages 1-15

  3. Regulatory Landscapes for Approval of Naturally-Derived Complex Mixture Drugs

    • Larisa C. Wu, Andre Raw, Werner Knöss, Michael Smith, Wei-Dong Zhang, Y. S. Bedi et al.
    Pages 17-44

  4. Complex Natural Product Heparin: Biosynthesis, Biology, and Application via Synthetic Heparins

    • Po-Hung Hsieh, Jian Liu
    Pages 45-58

  5. Traditional Chinese Medicine Herbal Drugs: From Heritage to Future Developments

    • Tai-Ping Fan, Yingli Zhu, Christine Leon, Gerhard Franz, Andreas Bender, Xiaohui Zheng
    Pages 59-77

  6. Analytics on Farm Dust Extract for Development of Novel Strategies to Prevent Asthma and Allergic Disease

    • Nathan Stebbins, Erika von Mutius, Ram Sasisekharan
    Pages 79-90

  7. Analytical Tools for Physicochemical Characterization and Fingerprinting

    • David A. Keire
    Pages 91-113

  8. NMR in the Characterization of Complex Mixture Drugs

    • Marco Guerrini, Timothy R. Rudd, Edwin A. Yates
    Pages 115-137

  9. Mass Spectrometry in the Characterization of Complex Drugs

    • Sarah Rogstad, Michael Boyne, Ashley Ruth
    Pages 139-155

  10. Scientific Considerations in the Approval of Complex Generics

    • Andre S. Raw, Larisa Wu
    Pages 157-173

  11. Raw Materials Production and Manufacturing Process Control Strategies

    • Suman Chandra, Donald Stanford, Edward Fletcher, Larry A. Walker
    Pages 175-190

  12. Heparin Contamination and Issues Related to Raw Materials and Controls

    • Yuanyuan Zhu, Fuming Zhang, Robert J. Linhardt
    Pages 191-206

  13. Pharmacology and Toxicology Concerns of Impurities

    • Daniel S. Marsman, Amy L. Roe
    Pages 207-217

  14. Immunogenicity Risks for Naturally Derived Complex Drugs

    • Roshni Rao, Daniela Verthelyi
    Pages 219-244

  15. Development of Plant-Derived Mixtures as Botanical Drugs: Clinical Considerations

    • Jinhui Dou, Julie Beitz, Robert Temple
    Pages 245-264

  16. A Totality-of-Evidence Approach to Ensuring Therapeutic Consistency of Naturally Derived Complex Mixtures

    • Sau L. Lee
    Pages 265-270

  17. Economic Considerations for Complex Mixture Drugs

    • Sen Lin
    Pages 271-295

  18. Drug Discovery from Complex Mixtures: Serendipity, Screening, and Characterization

    • Melissa Jacob, Xing-Cong Li, Larry A. Walker
    Pages 297-310

  19. Integrated Approach for Characterization of Highly Heterogeneous Drugs

    • Rahul Raman, Zachary Shriver, Thomas Clark, Ram Sasisekharan
    Pages 311-327

  20. Back Matter

    Pages 329-331
    Download chapter PDF
Back to top

Keywords

About this book

This volume in the AAPS Advances series covers various quality, safety and clinical aspects of drug development that are relevant to new and/or generic drugs containing a complex mixture of molecules. Specific topics discussed include: raw materials sourcing; manufacturing controls; characterization; identification of critical product quality components and attributes; identification of impurities, particularly as they bear on toxicity and immunogenicity; clinical trial study design considerations, and the regulatory science applications to development of such complex mixtures. Complex mixtures are challenging to characterize and analyze using standard methods. Further challenges extend throughout the product development cycle from raw material control to clinical study design.  The regulatory landscape is rapidly changing as new types of complex mixtures are introduced into clinical trials and to the market (e.g., traditional Chinese medicines and medical marijuana products), while older products are facing generic competition for the first time (e.g., enoxaparin). The future outlook for complex generic drug products, as opposed to the more commonly developed targeted single agent drug products is not clear.  The risks pertaining to lack of a full understanding of raw material control, process and controls in manufacture, as well as characterization of a complex mixture were seen vividly during the heparin crisis of 2008. As such powerful lessons have been learned about the regulatory science specific to complex products. The Science and Regulations of Naturally Derived Complex Drugs addresses the interests among industry, academics, and government on the issues surrounding the future development of mixtures for medicinal use.

Editors and Affiliations

  • Department of Biological Engineering, Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA

    Ram Sasisekharan

  • Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, USA

    Sau L. Lee, Amy Rosenberg

  • Director Emeritus, National Center for Natural Products Research, School of Pharmacy, University of Mississippi, Oxford, USA

    Larry A. Walker

About the editors

Amy Rosenberg received her medical degree from Albert Einstein College of Medicine and is Board Certified in Internal Medicine. She was a post-doctoral fellow in Al Singer’s Laboratory in the NCI before coming to CBER, FDA in 1988. She became Director of the Division of Therapeutic Proteins, CBER/CDER in 2000. Her division (now DBRR3 in the Office of Biotechnology Products, CDER) regulates diverse protein therapeutics, including monoclonal antibodies and fusion proteins, enzyme replacement therapies, hematologic and somatic cell growth factors, and immunomodulatory agents. She has been a driving force in risk evaluation and mitigation pertaining to the immunogenicity of therapeutic proteins (Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products) and in the elucidation and implementation of immune tolerance induction protocols in clinical settings. She previously co-edited the AAPS/Springer Book “Biobetters: Protein Engineering to Approach the Curative”. 

Larry A. Walker is Director Emeritus of the National Center for Natural Products Research (NCNPR) at the University of Mississippi, having retired at the end of 2016 after 15 years as director.  He has been a member of the faculty of the School of Pharmacy at Ole Miss for 37 years.  He took his undergraduate pharmacy training at Mercer University (1975), and his doctorate in Pharmacology from Vanderbilt University School of Medicine in 1979, He has worked for much of his career on natural products drug discovery, pharmacology, toxicology and metabolism. Dr. Walker is a co-author of more than 200 papers in peer-reviewed journals in pharmacology, toxicology, and natural products discovery and development.  He is a member of the American Society of Pharmacognosy, American Society of Pharmacology and Experimental Therapeutics, American Society of Microbiology, American Society of Tropical Medicine and Hygiene, American Association of Pharmaceutical Scientists. He has served on editorial boards of the Journal of Pharmacology and Experimental Therapeutics, Phytotherapy Research, and was the editor-in-chief of the Journal of Biomolecular Screening from 1999-2007. He received the University’s second Distinguished Research and Creative Achievement Award in 2009, and the School of Pharmacy’s Researcher of the Year Award in 2003.  He works presently on development of strategic partnerships for the University of Mississippi, and as a senior science advisor with ElSohly Laboratories, Inc. in Oxford, MS, and consultant for pharmaceutical and botanical supplement industries.  

 

 

 


Bibliographic Information

  • Book Title: The Science and Regulations of Naturally Derived Complex Drugs

  • Editors: Ram Sasisekharan, Sau L. Lee, Amy Rosenberg, Larry A. Walker

  • Series Title: AAPS Advances in the Pharmaceutical Sciences Series

  • DOI: https://doi.org/10.1007/978-3-030-11751-1

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: American Association of Pharmaceutical Scientists 2019

  • Hardcover ISBN: 978-3-030-11750-4Published: 03 May 2019

  • eBook ISBN: 978-3-030-11751-1Published: 23 April 2019

  • Series ISSN: 2210-7371

  • Series E-ISSN: 2210-738X

  • Edition Number: 1

  • Number of Pages: VI, 331

  • Number of Illustrations: 20 b/w illustrations, 41 illustrations in colour

  • Topics: Pharmaceutical Sciences/Technology, Pharmacy

Publish with us

Policies and ethics

Back to top

Search

Navigation